NCT05039177 2026-03-25
HERKULES-3
Erasca, Inc.
Phase 1/2 Completed
Clinical Trials
11 trialsNCT04585815 2026-01-09
Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
Pfizer
Phase 1/2 Terminated
NCT06194929 2025-12-03
DETERMINE
University of Utah
Phase 1/2 Recruiting
NCT04017650 2025-11-20
Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT03843775 2024-10-21
A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT04655157 2024-05-23
QUAD01
University of Pittsburgh
Phase 1/2 Terminated
NCT01543698 2024-03-13
A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors
Pfizer
Phase 1/2 Completed
NCT04720768 2024-01-05
CELEBRATE
Peter MacCallum Cancer Centre, Australia
Phase 1/2 Unknown
NCT02902042 2021-02-16
IMMU-TARGET
University Hospital, Essen
Phase 1/2 Completed
NCT02278133 2017-10-09
Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations
Array BioPharma
Phase 1/2 Completed
NCT01777776 2016-09-13
Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.
Array BioPharma
Phase 1/2 Terminated